Zacks Investment Research upgraded shares of Natera, Inc. (NASDAQ:NTRA) from a sell rating to a buy rating in a research note published on Thursday morning. Zacks Investment Research currently has $9.25 price objective on the medical research company’s stock.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

Several other research firms have also weighed in on NTRA. Canaccord Genuity lifted their target price on shares of Natera from $14.00 to $16.00 and gave the company a buy rating in a report on Wednesday, May 10th. BidaskClub lowered shares of Natera from a buy rating to a hold rating in a report on Tuesday, July 25th. Morgan Stanley reduced their target price on shares of Natera from $18.00 to $13.00 and set an overweight rating on the stock in a report on Monday, August 7th. Finally, ValuEngine lowered shares of Natera from a sell rating to a strong sell rating in a report on Monday, July 24th. Four investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Natera presently has an average rating of Hold and a consensus price target of $14.45.

Shares of Natera (NASDAQ NTRA) opened at 10.62 on Thursday. Natera has a 52 week low of $7.35 and a 52 week high of $12.95. The stock has a 50 day moving average price of $9.97 and a 200 day moving average price of $9.55. The firm’s market capitalization is $565.23 million.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.52). The business had revenue of $53.60 million for the quarter, compared to analyst estimates of $50.57 million. Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The business’s quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.46) EPS. Equities analysts forecast that Natera will post ($2.08) earnings per share for the current fiscal year.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/14/natera-inc-nasdaqntra-raised-to-buy-at-zacks-investment-research.html.

A number of institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors raised its position in shares of Natera by 7.3% in the first quarter. Nationwide Fund Advisors now owns 62,273 shares of the medical research company’s stock worth $552,000 after buying an additional 4,246 shares in the last quarter. Prudential Financial Inc. raised its position in shares of Natera by 185.9% in the first quarter. Prudential Financial Inc. now owns 73,820 shares of the medical research company’s stock worth $654,000 after buying an additional 48,000 shares in the last quarter. Massachusetts Financial Services Co. MA raised its position in shares of Natera by 1.2% in the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock worth $143,000 after buying an additional 194 shares in the last quarter. Capital Impact Advisors LLC purchased a new position in shares of Natera during the first quarter worth approximately $739,000. Finally, Citadel Advisors LLC raised its position in shares of Natera by 20.3% in the first quarter. Citadel Advisors LLC now owns 204,371 shares of the medical research company’s stock worth $1,813,000 after buying an additional 34,510 shares in the last quarter. Hedge funds and other institutional investors own 59.86% of the company’s stock.

About Natera

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related stocks with our FREE daily email newsletter.